Sirolimus Clinical Trial

The University of Pennsylvania and the University of Arkansas for Medical Sciences are conducting a research study of an investigational medicine for individuals between the ages of 18 and 80 who have idiopathic multicentric Castleman disease (iMCD) and are unable to benefit from anti-IL-6 therapies. Anti-IL-6 therapies are siltuximab (Sylvant) and tocilizumab (Actemra). If you are an iMCD patient who is currently experiencing disease activity and are either unable to tolerate anti-IL-6 therapy, or your disease does not respond to anti-IL-6 therapy, please contact the CSTL for additional information on this study. Participation in this study is entirely voluntary. 

Eligible participant will receive, at no cost, study related:

· Medical procedures

· Laboratory assessment

· Investigational medication

· Reimbursement for study travel may be available

More information about this trial can also be found at:

If you are interested in participating or have any questions about this study, please contact research staff:

Call: Tracey Sikora @ (215) 614-0199